Sentences with phrase «cu cancer»

«We are not sure why this is happening at the molecular level but evidence shows that people who take more dietary supplements than needed tend to have a higher risk of developing cancer,» explains Byers, associate director for cancer prevention and control at the CU Cancer Center.

Groups around the country have tried to create cell and animal models of ACC but haven't been successful,» says Katja Kiseljak - Vassiliades, DO, CU Cancer Center investigator and assistant professor in the CU School of Medicine Division of Endocrinology.

Previous work at CU Cancer Center shows these drugs are especially useful against lung cancers that over-express both EGFR and HER2, implying that in addition to targeting HER2 - positive lung cancers with drugs approved to treat HER2 - positive breast cancers, there may be a role for HER2 inhibitors in HER2 cancers, perhaps both breast and lung.

Now researchers working on canine cancer have an authenticated resource similar to what's available for human cancers,» says Daniel L. Gustafson, PhD, CU Cancer Center investigator and director for basic research at the Flint Animal Cancer Center.

The more it's expressed only on cancer cells, the more targeted the therapy becomes,» says Colin Weekes, MD, PhD, CU Cancer Center investigator and assistant professor in the Division of Oncology at the CU School of Medicine.

«This line of work is starting to change our thinking about who and when — the timing and patient selection for anti-androgen receptor therapy in triple - negative breast cancer,» says Valerie Barton, the study's first author and PhD candidate in the lab of CU Cancer Center investigator Jennifer Richer, PhD.

Dan Theodorescu, MD, PhD, James Costello, PhD, and CU Cancer Center colleagues show that whole - exome sequencing predicts bladder cancer sensitivity to cisplatin.

In a mechanism that Tan hopes will become common, his group will now hand off this rational combination to other researchers at the CU Cancer Center and elsewhere who will move the drugs toward a human clinical trial.

«In other words, we wanted to make sure these signatures were meaningful in real, human tumors and not just an artifact of being grown in a dish,» says James Costello, PhD, investigator at the CU Cancer Center and assistant professor in the CU School of Medicine Department of Pharmacology.

But this is a different disease and the treatments that work in sun - caused melanoma don't work in non-sun melanoma,» says William A. Robinson, MD, investigator at the CU Cancer Center and the Rella and Monroe Rifkin Endowed Chair of Medical Oncology at the CU School of Medicine.

«Even outside these specific findings with cancer, what we're saying is that flavonoids are active and not always in good or even predictable ways,» says Steven K. Nordeen, PhD, investigator at the CU Cancer Center and professor emeritus in the Department of Pathology at the CU School of Medicine.

«We have seen SF3B1 mutation in chronic lymphocytic leukemia and in myeloid dysplastic disorders, and now we show its importance in mucosal melanoma,» says Aik Choon Tan, PhD, investigator at the CU Cancer Center and associate professor of Bioinformatics at the CU School of Medicine.

Working at the CU Cancer Center, bioinformaticist Ken Jones, PhD, sifted through the data to compare these high - risk genomes with normal - risk genomes.

«These people are born with a broken gene and it sets them up for leukemia,» says Chris Porter, MD, investigator at the CU Cancer Center and associate professor in the Department of Pediatrics at the CU School of Medicine.

«Ultimately, the virus is suppressing the immune system for its own benefit, and promoting the formation and proliferation of cancer cells may be just a side effect of that,» says Sharon Kuss - Duerkop, PhD, research instructor working in the lab of CU Cancer Center investigator Dohun Pyeon, PhD.

In fact, a similar strategy led to similar results in bladder cancer, and a prospective clinical trial of COXEN in bladder cancer is underway at the CU Cancer Center and elsewhere.

«The model allowed us to ask what would have been the right drug in each case, how could we have known from the tumor's genetics, and what difference it made,» says Jennifer R. Diamond, MD, CU Cancer Center investigator and medical oncologist at the University of Colorado Hospital.

It's time for the Surgeon General to say the same thing about UV tanning,» says Robert P. Dellavalle, MD, PhD, MSPH, investigator at the CU Cancer Center, associate professor of dermatology at the University of Colorado School of Medicine, and the study's senior author.

However, along with this seemingly linear storyline in which retinoids block progesterone's promotion of CK5 + cells, previous work in the lab of CU Cancer Center investigator Peter Kabos, MD, and others shows that breast cancers treated with anti-estrogen drugs like tamoxifen or aromatase inhibitors show an increased population of CK5 + cells — it is as if these therapies remove the roadblock of estrogen - dependent cells, leaving CK5 + cells to proliferate.

«These are optimistic results for one of the first targeted therapies for cancer stem cells,» says Antonio Jimeno, MD, PhD, investigator at the CU Cancer Center, director of the university's Cancer Stem Cell - Directed Clinical Trials Program, and principal investigator of the clinical trial at the CU Cancer Center site.

Previous work in the lab of CU Cancer Center investigator, Carol Sartorius, PhD, and others shows that progesterone aids the expansion of CK5 + cells.

Three trials are now open for OMP - 54F28 (FZD8 - Fc) in combinations with standard therapy for pancreatic, ovarian and liver cancers, being offered at the CU Cancer Center and elsewhere.

In the context of the collaboration between the Gates Center for Stem Cell Biology and the CU Cancer Center this was the second clinical trial we offered to our patients with the specific intent to eliminate the CSCs in their tumors.»

«We know about the dose - limiting side - effects of liposomes, but no one had looked at what happens to the liposome over time in the skin — how they get there and what happens to liposomes after injection,» says Dmitri Simberg, PhD, investigator at the CU Cancer Center and the paper's senior author.

For the current study, working in the CU Cancer Center Advanced Light Microscopy Core, co-authors Dominik Stitch, PhD, and Radu Moldovan, PhD, implemented a new technique known intravital multiphoton in vivo microscopy that enabled the team to watch fluorescent - tagged liposomes in real - time after injection.

Not exact matches

Co-author Dr. Susan Cu - Uvin, professor of public health and of obstetrics and gynecology at Brown, said women with HIV are especially susceptible to cervical cancer from HPV because their weakened immune systems are less able to clear the virus.

«For someone to go up against alectinib, it would be nice to know earlier if there might be an improvement,» says Robert C. Doebele, MD, PhD, investigator at the University of Colorado Cancer Center and associate professor of Medical Oncology at the CU School of Medicine.

And so the challenge is matching drugs with many effects to cancers with many causes in a way that best maps the drugs» effects onto the intended targets,» says Aik Choon Tan, PhD, investigator at the University of Colorado Cancer Center and associate professor of Bioinformatics at the CU School of Medicine.

«Knowing this mechanism that underlies IL - 37's effect on the immune system now allows us to study IL - 37 function and perhaps dysfunction in a wide range of diseases,» says Mayumi Fujita, MD, PhD, investigator at the University of Colorado Cancer Center, associate professor in the CU School of Medicine Department of Dermatology, and the paper's senior author.

We're discovering new genetic alterations driving lung cancer, new drugs to target these alterations, and are refining our use of tests to find these alterations in individual patients,» says Dara Aisner, MD, PhD, investigator at the University of Colorado Cancer Center, molecular pathologist at CU School of Medicine Department of Pathology, and one of the panel excancer, new drugs to target these alterations, and are refining our use of tests to find these alterations in individual patients,» says Dara Aisner, MD, PhD, investigator at the University of Colorado Cancer Center, molecular pathologist at CU School of Medicine Department of Pathology, and one of the panel exCancer Center, molecular pathologist at CU School of Medicine Department of Pathology, and one of the panel experts.

A recent study by the University of Colorado Cancer Center and CU School of Medicine examined obese rats with breast cancer and found some important insCancer Center and CU School of Medicine examined obese rats with breast cancer and found some important inscancer and found some important insights.